CPRX — Catalyst Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- $2.40bn
- $2.02bn
- $398.20m
- 84
- 38
- 86
- 79
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 94.5 | 140 | 191 | 298 | 138 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 10.5 | 5.99 | 6.62 | 10.4 | 53.5 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 111 | 159 | 210 | 321 | 219 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1 | 0.13 | 3.98 | 3.62 | 3.7 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 112 | 192 | 238 | 376 | 470 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 24.1 | 22.8 | 27.1 | 57.6 | 76.1 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 24.7 | 22.8 | 31 | 75.2 | 82.2 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 87.6 | 170 | 207 | 300 | 388 |
Total Liabilities & Shareholders' Equity | 112 | 192 | 238 | 376 | 470 |
Total Common Shares Outstanding |